VISTA

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

Retrieved on: 
Giovedì, Maggio 23, 2024
Clinical research, Patient, Pharmacokinetics, Juan Carlos Ferrero, Interleukin, VISTA, FDA, Sensei, Endometrial cancer, Safety, PD-1, Cancer, TMDD, ASCO, CRC, Kinetics, Poster, Society, Aes, Therapy, Immunotherapy, Webcast, NEXT, Antibody, MSS, CRS, Tumor necrosis factor, Pharmaceutical industry

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

Key Points: 
  • There is a continued unmet need for patient populations that have become resistant or don’t respond to current immunotherapy treatment options.
  • I look forward to continuing to evaluate its progress.”
    The dose escalation portion of the Phase 1/2 clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101.
  • These clinical data are consistent with preclinical studies suggesting therapeutically relevant clinical doses of SNS-101 at 3mg/kg or higher.
  • Dr. Sen is an investigator on the ongoing Phase 1/2 clinical trial for SNS-101, and lead author of the SNS-101 poster.

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

Retrieved on: 
Mercoledì, Maggio 15, 2024
Patient, CPI, Pembrolizumab, VISTA, Workforce, NK, Clinical trial, Lung cancer, Bone marrow, AACR, Safety, Kineta, Cytokine release syndrome, CD27, AML, Cancer, Research, Chemokine, Biomarker, Infrared spectroscopy correlation table, Combination, Public expenditure, Failure, Acute myeloid leukemia, Pharmaceutical industry

“The Company announced additional clinical updates on the progress of the KVA12123 monotherapy and combination therapy results during the first quarter of 2024.

Key Points: 
  • “The Company announced additional clinical updates on the progress of the KVA12123 monotherapy and combination therapy results during the first quarter of 2024.
  • We continue to be pleased with these early clinical results as well as the accompanying biomarkers and immune cell data sets.
  • We look forward to sharing additional clinical updates in the second quarter and we will continue to explore strategic alternatives,” said Craig Philips, President of Kineta.
  • Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Giovedì, Maggio 9, 2024
FDA, Cancer, Nature Communications, Research and development, DLT, MSS, Safety, Pharmacokinetics, Colorectal cancer, CRC, Tumor microenvironment, VISTA, Sensei, IND, Administration, Part-time, ASCO, Keystone, Therapy, Patient, Society, Histology, Neoplasm, Biology, VSIG4, CD39, Annual general meeting, NSCLC, Lung cancer, Pharmaceutical industry

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided corporate updates.

Key Points: 
  • BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided corporate updates.
  • In January 2024, Sensei announced a realignment of its resources to fully support the Phase 1/2 clinical trial of SNS-101.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.8 million for the quarter ended March 31, 2024, compared to $5.8 million for the quarter ended March 31, 2023.
  • Net Loss: Net loss was $8.0 million for the quarter ended March 31, 2024, compared to $10.2 million for the quarter ended March 31, 2023.

U.S. Air Force Secretary Kendall Flies in AI-piloted X-62A VISTA

Retrieved on: 
Venerdì, Maggio 3, 2024
Aircraft, AIR, DARPA, ACE, Society, Architecture, LMT, Certification, AI, SACS, Software, Lockheed Martin, Artificial intelligence, VISTA, Aviation, MFA, Lockheed, Government, Algorithm, Simulation, Defense, Skunk Works, Jet fuel

EDWARDS AIR FORCE BASE, Calif., May 3, 2024  /PRNewswire/ -- Lockheed Martin Skunk Works® (NYSE: LMT) joined the U.S. Air Force Test Pilot School and other government and industry partners in hosting U.S. Secretary of the Air Force Frank Kendall to fly in the X-62A Variable In-flight Simulation Test Aircraft (VISTA), a one-of-a-kind aircraft modified to test artificial intelligence (AI) and autonomy capabilities.

Key Points: 
  • EDWARDS AIR FORCE BASE, Calif., May 3, 2024 /PRNewswire/ -- Lockheed Martin Skunk Works® (NYSE: LMT) joined the U.S. Air Force Test Pilot School and other government and industry partners in hosting U.S. Secretary of the Air Force Frank Kendall to fly in the X-62A Variable In-flight Simulation Test Aircraft (VISTA), a one-of-a-kind aircraft modified to test artificial intelligence (AI) and autonomy capabilities.
  • VISTA is an AI pathfinder that facilitates development and testing of cutting-edge AI techniques with new uncrewed vehicle designs.
  • "Our proven hardware and software architecture enable safe and controlled environments for AI agents and advanced algorithms to rapidly prototype and develop."
  • This architecture has proven to be reliable and robust enough to transition into third-party distributed hardware to replicate safe and controlled flight test objectives as demonstrated by VISTA.

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Retrieved on: 
Mercoledì, Aprile 24, 2024
ASCO, Therapy, Cancer, Annual general meeting, Patient, Society, VISTA

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.

Key Points: 
  • BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.

Citadel Credit Union Reinforces Commitment To The Communities It Serves Through Ongoing Initiatives Amid Continued Growth

Retrieved on: 
Martedì, Aprile 16, 2024
Citadel, Online, Daily Local News, Education, Credit union, CHOP, Local news, Annual report, Citadel Credit Union, Wellness, Partnership, VISTA, Retirement, FFD, Food security, Growth, Key, Online shopping

EXTON, Pa., April 16, 2024 /PRNewswire/ -- Citadel Credit Union is reinforcing its dedication to supporting the communities it serves across the Chester, Bucks, Delaware, Montgomery, Lancaster, and Philadelphia counties through ongoing community initiatives.

Key Points: 
  • EXTON, Pa., April 16, 2024 /PRNewswire/ -- Citadel Credit Union is reinforcing its dedication to supporting the communities it serves across the Chester, Bucks, Delaware, Montgomery, Lancaster, and Philadelphia counties through ongoing community initiatives.
  • Citadel employees have also been on the receiving end multiple times of VISTA Today's Millennial Superstars 40 Under 40 awards .
  • "Since joining Citadel in late 2023, I've been proud to become a part of the team's ongoing efforts to achieve growth and stability while enhancing Citadel's presence in our communities," said Bill Brown, President and CEO, Citadel Credit Union.
  • Throughout the year, Citadel continued to have strong deposit growth at 2.5% percent from the prior year.

Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%

Retrieved on: 
Lunedì, Marzo 18, 2024
Cloud, Research, SKQ1, Quality control, Weather, NMPA, Therapeutic Goods Administration, Environment, Best, Intelligence, Patent, Patient, Conditional sentence, Ophthalmology, Hospital, POCT, Acquisition, CMC, European Medicines Agency, GMP, City, QMS, Bevacizumab, Chemistry, Yoy, US FDA, Traction, Good, Therapy, Point-of-care testing, VISTA, Pharmaceutical industry

The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.

Key Points: 
  • The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.
  • As of 31 December 2023, the Group had cash and cash equivalents of approximately HK$509.8 million (2022: approximately HK$543.5 million).
  • Together with the interim dividend of HK$0.045 per ordinary share paid on 13 September 2023, the total dividend for 2023 would be HK$0.09 (2022: HK$0.065) per ordinary share.
  • The Group's turnover is primarily made up of the ophthalmology segment ("Ophthalmology") and surgical (wound care and healing) segment ("Surgical").

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

Retrieved on: 
Martedì, Aprile 9, 2024
NEXT, Therapy, Patient, Conference, Canaccord Genuity, VISTA, Cancer

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m.

Key Points: 
  • BOSTON, April 09, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m.
  • ET.
  • The panel will feature Dr. Shiraj Sen, M.D., Ph.D., Medical Oncologist and Director of Clinical Research at NEXT Oncology-Dallas.
  • Dr. Sen is an investigator on the ongoing Phase 1/2 clinical trial for SNS-101.

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Retrieved on: 
Lunedì, Aprile 8, 2024
Combination, CPI, Immunosuppression, Patient, Tumor microenvironment, Immunoglobulin G, Merck, Cancer, Pembrolizumab, Lung cancer, AACR, DLT, Clinical trial, Merck & Co., Kineta, NK, VISTA, Pharmaceutical industry

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors.

Key Points: 
  • KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
  • KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
  • Patients currently enrolled in the trial will be permitted to continue to participate.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Retrieved on: 
Giovedì, Aprile 4, 2024
Risk, Sensei, Patient, Research, Tumor microenvironment, Manuscript, CRS, Cancer, Trial of the century, Cytokine release syndrome, Myelocyte, Antibody, Safety, Therapy, VISTA, Nature Communications, PD-1, Vaccine

The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.

Key Points: 
  • The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.
  • The paper describes Sensei Biotherapeutics’ approach to the discovery and development of SNS-101, which was designed to potently and selectively target the active protonated form of VISTA, a protein that plays a significant role in suppressing T-cell activation.
  • SNS-101 is designed to block VISTA by inhibiting its interaction with PSGL-1 on T-cells resulting in T-cell activation.
  • The manuscript published in Nature Communications is entitled “VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response,” and can be found here: https://rdcu.be/dDF8x